Explore the latest developments in oncology research
Since 2015, the FDA has approved nearly 140 new cancer drugs, about a quarter of the almost 500 medicines it’s cleared for market during that time. The long list of new treatments reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.
Included in this Trendline:
- Lilly adds to new wave of oral drugs for advanced breast cancer
- Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
- Inside AstraZeneca’s long-term strategy in lung cancer
Offered Free by: BioPharma Dive and Bio-Rad
See All Resources from: BioPharma Dive and Bio-Rad
